As shown in Table S2, in AML patients with intermediate and adverse-cytogenetic risk, older age, TP53 mutation, and DNMT3A mutation were all significantly related to a lower 2-year OS rate in addition to IPM-HR (all P < 0.05). This evidence concerns the gene TP53 and acute myeloid leukemia.